Horizon Therapeutics Public Limited Company (HZNP) has seen some recent movement in the marketplace and its stock finished trading at $42.03 yesterday. Traders are starting to take notice of HZNP as the stock traded as high as $43.10 and as low as $41.33 in the previous market trading day.

Horizon Therapeutics Public Limited Company (HZNP) average trading volume is 2.08M. However, in the previous market trading day Horizon Therapeutics Public Limited Company (HZNP) traded 4,167,198 shares. The first downside support level on HZNP is $40.00. HZNP 50 day moving average is $31.71 and HZNP 200day moving average is $33.02.

Horizon Therapeutics Public Limited Company (HZNP) most current performance has been indicated by the recent movement in HZNP stock. HZNP has performed 36.64% over the past month, HZNP has performed 19.10% over the past quarter and HZNP has shown 55.90% over the past 1 year. Horizon Therapeutics Public Limited Company (HZNP) has a 1 year range of $22.69 to $43.90. Horizon Therapeutics Public Limited Company (HZNP) is trading 85.24% from its 1 year low and -4.26% from its 1 year high. Horizon Therapeutics Public Limited Company (HZNP) is showing a 4.96% short float showing the quantity short in the float.

HZNP has 192.40M shares outstanding and 187.62M shares in the float. Horizon Therapeutics Public Limited Company (HZNP) at this time has a market cap of $8.09B and income of $573.00M. The EPS next quarter for HZNP is 0.22 and anticipated EPS net year is 33.83%. The market cap of Horizon Therapeutics Public Limited Company (HZNP) at $8.09B represents how many Traders own shares of HZNP and is based off the last price ($42.03) of HZNP and the quantity of shares outstanding (192.40M) with Horizon Therapeutics Public Limited Company (HZNP).

Horizon Therapeutics Public Limited Company (HZNP) has total cash (mrq) of 1.08B, total cash per share (mrq) of 5.67, total debt of HZNP remains at 1.4B and total debt/equity (mrq) is 64.23. Horizon Therapeutics Public Limited Company (HZNP) operating cash flow (ttm) is 426.33M and HZNP leveraged free cash flow (ttm) is 352.72M.

HZNP is trading 23.30% above (bullish) its SMA20, 31.75% above (bullish) its SMA50 and 35.90% above (bullish) its SMA200.

Recent News:

In recent news, on May 6, 2020, it was announced, Horizon Therapeutics plc Reports Strong First-Quarter 2020 Financial Results; Increasing TEPEZZA™ Full-Year 2020 Net Sales Guidance to Greater Than $200 Million Due to Rapid Uptake; Increasing Full-Year 2020 Net Sales Guidance. In this news it stated, — First-Quarter 2020 Net Sales of $355.9 Million Increased 27 Percent;First-Quarter 2020 GAAP Net Loss of $13.6 Million; Adjusted EBITDA of $107.2 Million — Orphan Segment First-Quarter 2020 Net Sales of $245.4 Million, an Increase of 47 Percent;KRYSTEXXA® First-Quarter 2020 Net Sales of $93.3 Million, an Increase of 78 Percent —

About Horizon Therapeutics Public Limited Company (HZNP):

Dublin, Ireland-based Horizon Therapeutics plc, previously known as Horizon Pharma plc, is a biopharmaceutical focused on making drugsts in arthritis, pain, inflammatory and orphan diseases areas. Horizon Therapeutics (Horizon) was formed in September 2014, after Horizon, and Vidara acquired Ireland-based privately held specialty pharmaceutical company, Vidara Therapeutics International Ltd. through a reverse merger.